Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults

Fig. 1

Assessment of Olipudase Alfa on Spleen Volumes

A. Individual patient spleen volumes by years of olipudase alfa treatment. Spleen volumes were calculated by integrating cross-sectional magnetic resonance images and expressed as multiples of normal (MN) where normal spleen volume was assumed to be 0.2% of body weight [18]. Severe and moderate splenomegaly were defined as > 15 and > 5 to ≤ 15MN, respectively [18]. Cutoffs of MN for severity of splenomegaly are indicated by horizontal lines

B. Least square (LS) mean percent changes ± SE of the mean in spleen volume from baseline over time. All p values are nominal

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172